Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

Christine M Fillmore; Chunxiao Xu; Pooja T Desai; Joanne M Berry; Samuel P Rowbotham; Yi-Jang Lin; Haikuo Zhang; Victor E Marquez; Peter S Hammerman; Kwok-Kin Wong; Carla F Kim

doi:10.1038/s41586-018-0580-6

Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

Nature. 2018 Nov;563(7732):E27. doi: 10.1038/s41586-018-0580-6.

Authors

Christine M Fillmore^{1

2

3}, Chunxiao Xu^{4

5}, Pooja T Desai¹, Joanne M Berry¹, Samuel P Rowbotham^{1

2

3}, Yi-Jang Lin², Haikuo Zhang^{4

5}, Victor E Marquez⁶, Peter S Hammerman⁴, Kwok-Kin Wong^{4

5}, Carla F Kim^{7

8

9}

Affiliations

¹ Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA.
² Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA.
³ Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA.
⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA.
⁵ Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, USA.
⁶ Chemical Biology Laboratory, National Cancer Institute, National Institutes of Health, Frederick, Maryland, 21702, USA.
⁷ Stem Cell Program, Boston Children's Hospital, Boston, Massachusetts, 02115, USA. carla.kim@childrens.harvard.edu.
⁸ Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA. carla.kim@childrens.harvard.edu.
⁹ Harvard Stem Cell Institute, Cambridge, Massachusetts, 02138, USA. carla.kim@childrens.harvard.edu.

PMID: 30250255
DOI: 10.1038/s41586-018-0580-6

Abstract

We wish to correct two mutations in Supplementary Table 4 of this Letter. The NCI-H460 cell line was annotated as being mutant for TP53. NCI-H460 has been verified to be TP53 wild type by several sources¹. The NCI-H2009 cell line was annotated as being mutant for PIK3CA. As annotated by COSMIC (ref. 24 of the original Letter) and CCLE (ref. 25 of the original Letter), the NCI-H2009 cell line has a mutation in PIK3C3, rather than PIK3CA. The cell line is wild type for PIK3CA. The Supplementary Information of this Amendment contains the corrected Supplementary Table 4. These errors do not affect our conclusions. The original Letter has not been corrected.

Publication types

Published Erratum